메뉴바로가기 본문바로가기

Technology

인류의 안전과 건강 증진에 기여하는 기업, (주)인테라입니다.

Platform Technology

01E.coli – based VLP Manufacturing Platform as an innovative solution against unmet and emerging viral infection
※ VLP : structurally resembling infectious virions, but non-infectious due to the lack the viral genome required for replication
02RIPT (RNA-Interaction mediated Protein manufacturing Technology)
High-yield & Fast VLP Manufacturing Platform Technology
03Strengths of E.coli-based VLP Vaccine
Conventional Viral Vaccine Manufacturing Process
Competitiveness of InThera VLP Vaccine
  • 01. Virus Propagation
    E.coli culture, instead of
    mammalian cell culture

    Increased facility efficiency and VLP manufacturing speed
  • 04. Purification
    High-level expression of capsid protein
    Purification through simple &
    convenient process

    Improved unwanted effect due to high purity
  • 05. Inactivation
    No denaturation of antigen
    due to the lack of
    chemical inactivation process

    Improved immunogenicity